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Abstract
Background: According to the World Health Organization’s recent report, in Malaysia, tuberculosis (TB) treatment
success rate for new smear positive pulmonary tuberculosis (PTB) patients is still below the global success target of
85%. In this study, we evaluated TB treatment outcome among new smear positive PTB patients, and identified the
predictors of unsuccessful treatment outcome and longer duration of treatment (i.e., > 6 months).
Methods: The population in this study consisted of all new smear positive PTB patients who were diagnosed at the
chest clinic of Penang General Hospital between March 2010 and February 2011. During the study period, a
standardized data collection form was used to obtain socio-demographic, clinical and treatment related data of the
patients from their medical charts and TB notification forms (Tuberculosis Information System; TBIS). These data
sources were reviewed at the time of the diagnosis of the patients and then at the subsequent follow-up visits until
their final treatment outcomes were available. The treatment outcomes of the patients were reported in line with
six outcome categories recommended by World Health Organization. Multiple logistic regression analysis was used
to find the independent risk factors for unsuccessful treatment outcome and longer treatment duration. Data were
analyzed using the PASW (Predictive Analysis SoftWare, version 19.0. Armonk, NY: IBM Corp).
Results: Among the 336 PTB patients (236 male and 100 female) notified during the study period, the treatment
success rate was 67.26% (n = 226). Out of 110 patients in unsuccessful outcome category, 30 defaulted from the
treatment, 59 died and 21 were transferred to other health care facilities. The mean duration of TB treatment was
8.19 (SD 1.65) months. In multiple logistic regression analysis, risk factors for unsuccessful treatment outcome
were foreign nationality, male gender and being illiterate. Similarly, risk factors for mortality due to TB included
high-grade sputum and presence of lung cavities at the start of treatment, being alcoholic and elderly. Likewise,
concurrent diabetes, presence of lung cavities at the start of the treatment and being a smoker were the significant
predictors of longer treatment duration.
Conclusion: Our findings indicated that the treatment success rate among the new smear positive PTB patients was
less than the success target set by World Health Organization. The proportion of patients in the successful outcome
category may be increased by closely monitoring the treatment progress of the patients with aforementioned high risk
characteristics. Similarly, more aggressive follow-up of the treatment defaulters and transferred out patients could also
improve the TB treatment success rate.
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Background
Tuberculosis (TB) is a public health problem with an an-
nual incidence rate of about 8.6 million cases and an esti-
mated 1.3 million deaths every year [1]. TB ranks as
second major cause of adult mortality from an infectious
disease worldwide, after human immunodeficiency virus
(HIV) [1]. It has been estimated that between the years
2000 and 2020, approximately one billion people will be
infected with Mycobacterium tuberculosis, 200 million in-
fected people will develop active disease, and 35 million
will die from TB globally if prevention and control plans
are not further developed and executed [2]. Assessment of
treatment outcome of newly diagnosed smear positive
pulmonary tuberculosis (PTB) patients is used as a major
pointer to gauge the effectiveness of national tuberculosis
program (NTP). World Health Organization (WHO) has
recommended that countrywide cohort analysis of TB
treatment outcome should be performed every year. This
strategy not only enables the NTP managers and staff to
identify the problems but also allows them to take ad-
equate and timely actions to improve the overall perform-
ance of the program [3-5].
According to WHO, TB treatment success rate among
new smear positive PTB patients in Malaysia is still
below the success target of 85% [1]. To date, a few stud-
ies from different states of Malaysia had reported the
treatment outcome of TB patients with a very high het-
erogeneity in the results [6-8]. Neither of these studies
had separately reported the treatment outcome of new
smear positive TB patients, nor do any of these studies
have established a link between patient characteristics
and mortality during TB treatment. Furthermore, exist-
ing data are also lacking in terms of establishing a rela-
tionship between patient characteristics and duration of
TB treatment.
Based on the WHO recommendations and the gaps
in the existing literature, the aims of this study are to
evaluate the treatment outcomes of new smear positive
PTB patients as well as to determine risk factors for




The study was conducted at the chest clinic of Penang
General Hospital (PGH). Penang General Hospital, with
a capacity of 1,107 beds, is a point-of-reference tertiary
health care facility in the Northern Region of Malaysia.
The chest clinic of PGH is under the respiratory depart-
ment with 70 beds [9]. In general, new PTB patients are
not hospitalized.
At the chest clinic, a minimum of five to six medical of-
ficers manage routine patients with respiratory illnesses,
whereby complex cases are managed by three full-time
chest consultants. In addition to this, the chest clinic has
dedicated paramedic staff to provide quality care to the
patients. The TB diagnostic laboratory, which is situated
adjacent to the chest clinic, has dedicated facility to inves-
tigate the specimens of suspected and existing TB patients
using sputum smear examination, culture, nucleic acid
amplification tests and drug sensitivity testing. The radi-
ology and pathology departments of PGH also provide
routine investigation services to TB patients.
Confirmed TB patients are advised to take their medi-
cation either at the chest clinic or at a primary health
care unit. In general, patients are advised to take their
daily medication under the direct observation of a staff
nurse at the chest clinic or at a primary health care unit.
However, some patients are allowed weekly packing of
the daily dose. Weekly packing of the daily dose is only
available at the chest clinic. Patients who continue their
daily TB medication at a primary health care unit are ad-
vised to visit the chest clinic (every two weeks during
the intensive phase and every month during the continu-
ation phase) for routine investigation. Patients who de-
fault from their treatment for five consecutive days are
traced by a team of staff comprising of a TB-coordinator,
a staff nurse and an attendant [10].
Study design and data collection
The population in this study consisted of all new smear
positive PTB patients (N = 336) who were diagnosed at
the study site between March 2010 and February 2011.
A patient diagnosed with smear positive PTB as well as
extrapulmonary tuberculosis (EPTB) was categorized as
a case of PTB, and therefore was included in the study.
The selection of this subgroup of patients was based on
the recommendation of WHO to separately evaluate
new smear positive PTB patients for the assessment of
NTP’s performance [3].
During the study period, a standardized data collection
form was used to obtain patient’s socio-demographic, clin-
ical and treatment related data on age, sex, ethnicity, mari-
tal status, smoking habit, alcohol use, drug abuse, presence
of any concurrent illness, site of disease, signs and symp-
toms of TB, chest X-ray findings, bacteriology results, dur-
ation of treatment and treatment outcome from his/her
medical chart and TB notification form (Tuberculosis
Information System, TBIS). Medical charts and notifica-
tion forms of all the patients were reviewed at the time of
their diagnosis and then at the subsequent follow-up
visits until final treatment outcomes of all the patients
were available (i.e., mid of December 2011). Some of the
socio-demographic characteristics (i.e., employment sta-
tus, monthly income and level of education) were obtained
by interviewing the patients by a trained nurse [7,11].
During the treatment, the clinicians prescribed stand-
ard 6 months treatment regimen (2 months of isoniazid,
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rifampicin, pyrazinamide and ethambutol during inten-
sive phase and 4 months of isoniazid and rifampicin dur-
ing the continuation phase) to the patients [3]. However,
for those patients who were still smear positive after
2 months of treatment and/or had cavitary disease at the
start of the treatment received longer treatment with
first-line anti-TB drugs [12-14]. As a result, 132 patients
had 3 months of intensive phase, while continuation
phase was prolonged (>4 months; maximum 7 months)
in 141 patients (Note: a patient whose intensive phase
was prolonged may or may not have prolonged continu-
ation phase). Similarly, treatment duration also varied
among those (n = 9) experiencing major side effects as-
sociated with anti-TB drugs [3].
The treatment outcomes of TB patients were reported
according to six outcome categories as mentioned in
the WHO guidelines [3]. These categories include; cured
(a patient who has completed TB treatment with nega-
tive bacteriology result in the last month of the treat-
ment and on at least one previous occasion), treatment
completed (a patient who has completed TB treat-
ment, but without the evidence of negative bacteri-
ology result in the last month of the treatment and on
at least one previous occasion), treatment failure (a pa-
tient in whom bacteriology result remains positive at
five months or later), died (a patient who died due to TB
or other cause during TB treatment), defaulter (a patient
whose TB treatment was interrupted for two consecutive
months or more after registration), transferred out (a
patient who has been referred to another recording
and reporting unit, and whose treatment outcome was
not available).
Cured and treatment completed were further summa-
rized as treatment success [3,4] whereas, treatment fail-
ure, died, defaulter and transferred out represented
unsuccessful treatment outcome [11,15-18].
The study was approved by the Medical Research
Ethics Committee (MERC), Ministry of Health, Malaysia




The total duration of TB treatment longer than 6 months
represented prolonged treatment duration [3].
High-grade sputum
Sputum was graded according to the number of acid-
fast bacilli (AFB) visible at the time of sputum smear mi-
croscopy. To simplify the grading categories, four grades
were (i.e., scanty positive, 1+, 2+ and 3+) were combined
to two categories. Scanty positive and 1+ represented low-
grade sputum, whereby 2+ and 3+ denoted high-grade
sputum [19].
Statistical analysis
Data were analyzed using the PASW (Predictive Analysis
SoftWare, version 19.0. Armonk, NY: IBM Corp). Simple
logistic regression analysis was used to examine the pos-
sible association between the dependent variables (i.e.,
unsuccessful outcome, death and prolonged treatment
duration) and selected socio-demographic and clinical
variables. The variables which were statistically signifi-
cant (i.e., p-value <0.05) in univariate analysis were en-
tered into a multiple logistic regression analysis to
predict the final independent factors. The adjusted odd
ratios (AOR), 95% confidence interval (CI), beta, stand-
ard error and p-value were reported for each predictor.
The model fit was assessed by chi-square, degrees of
freedom and p-value. Pseudo R square values were re-
ported to provide information about the percentage of
variance explained by the model. A p-value of <0.05 was
considered statistically significant [4,15,17].
Results
During the study period, a total of 594 TB patients (all
forms) were registered at the study site. However, 336
new smear positive PTB patients (56.57%) were in-
cluded in the study. The mean age of the enrolled pa-
tients was 49.11 (SD 16.58) years. Table 1 provides the
inclusive details about socio-demographic characteris-
tics of the patients.
Of the 336 study patients, approximately 97% patients
had pulmonary disease, while only 2.98% were the con-
firmed cases of PTB and EPTB. The mean duration of
TB treatment was 8.19 (SD 1.65) months. Table 2 pro-
vides a full description of the clinical characteristics of
the patients.
Standardized treatment outcomes
Table 3 illustrates proportion of the patients in successful
and unsuccessful treatment outcome categories. Out of
226 (67.26%) successfully treated patients, only 12.20% pa-
tients were classified as cured. In terms of unsuccessfully
treated patients, 59 died, while 30 defaulted from the
treatment. A relatively small proportion of the patients
(n = 21) were transferred to other health care facilities.
Predictors of unsuccessful treatment outcome
In multiple logistic regression analysis, the factors which
remained significantly associated with unsuccessful treat-
ment outcome were foreign nationality (AOR 21.24; 95%
CI 4.61, 97.94), being illiterate (AOR 3.72; 95% CI 1.56,
8.87) and male gender (AOR 2.15; 95% CI 1.20, 3.87)
(Table 4).
As described earlier, the proportion of patients died dur-
ing TB treatment accounted for approximately 54% (i.e.,
59 out of 110 patients) of the total patients in unsuccessful
treatment outcome category. Therefore, further analysis
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was conducted to identify the factors which were signifi-
cantly associated with the death of the patients.
In multiple logistic regression analysis, the factors which
remained significantly associated with patients’ mortality
were high-grade sputum at the start of treatment (AOR
11.19; 95% CI 2.50, 30.11), presence of lung cavities at the
start of the treatment (AOR 7.25; 95% 2.76, 19.07), being
alcoholic (AOR 2.54; 95% CI 1.17, 5.51) and being older
(AOR 1.03; 95% CI 1.01, 1.06) (Table 5).
Predictors of prolonged treatment duration
In multiple logistic regression analysis, determinants of
prolonged treatment duration (i.e., more than 6 months)
were concurrent diabetes (AOR 6.80; 95% CI 2.98,
15.51), presence of lung cavities at the start of the treat-
ment (AOR 2.67; 95% 1.29, 5.77) and being a smoker
(AOR 2.43; 95% 1.18, 5.03) (Table 6).
Discussion
In our study, TB treatment success rate among new smear
positive PTB patients was 67.26%. This was less than the
target success rate for new smear positive PTB patients.
According to a recent report, the TB treatment success
rate in Malaysia is declining [20]. One of the possible rea-
sons for this decline over the past few years could be
the influx of increasing number of people from neighbor-
ing countries seeking employment in Malaysia. Studies
showed that foreigners either prefer to be transferred to
their countries or defaulted from the treatment due to
the fear of compulsory expulsion by the immigration au-
thorities [15,21]. Similar to the findings of our study, two
African studies also reported low treatment success rate
in TB patients [17,22]. Likewise, in recent years, TB treat-
ment success rate (new smear positive PTB cases) in
Japan, Hong Kong and Fiji was less than 70%. Similarly,
other developed countries from Western Pacific Region
like Australia, New Zealand and Singapore showed a treat-
ment success rate of less than 80% in new smear positive
PTB patients [1].
As described in the Results section, one of the major
reasons for non-attainment of success target was the
higher death rate (17.56%) among the patients. Published
Table 1 Socio-demographic characteristics of the patients
Characteristics Patients n (%) Characteristics Patients n (%)
Sex Drug abuser
Male 236 (70.24) Yes 30 (8.93)
Female 100 (29.76) No 306 (91.07)
Age group (years) Smoking status
≤24 30 (8.93) Smoker 175 (52.08)
25–34 41 (12.20) Non-smoker 161 (47.92)
35–44 56 (16.67) Alcoholism
45–54 77 (22.92) Yes 115 (34.23)
55–64 71 (21.13) No 221 (65.77)
65–74 37 (11.01) Employment status
≥75+ 24 (7.14) Employed 256 (76.19)
Ethnicity Unemployed 80 (23.81)
Malay 104 (30.95) Monthly income (MYR*)
Chinese 179 (53.27) ≤1000 134 (39.88)
Tamil 33 (9.82) 1001–2000 136 (40.48)
Foreigners 20 (5.95) 2001–4000 48 (14.29)
Marital status 4001–6000 13 (3.87)
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data from the United States and Western Pacific Region
showed that the death rates among TB patients ranged
from 14–21% [1,23,24]. Ditah et al stated that in some of
the deaths, TB is only incidental and not causal. Further-
more, they emphasized that it is unreasonable to consider
such deaths as unsuccessful treatment outcome of TB
[11]. Likewise, a study from Russia further highlighted that
using such deaths during TB treatment as an indicator of
NTP’s performance might be misleading, and that these
deaths might not have been preventable even with im-
provements in the TB services [25]. Studies from the
United Kingdom and Switzerland reported that WHO’s
target of 85% treatment success rate was missed mainly
due to a higher proportion of deaths, mostly due to causes
other than TB [5,26]. Consequently, based on the reason-
ing and recommendations given in the above cited studies,
the treatment success rate in the present cohort analysis
could be raised to 73.85% (by excluding 30 patients from
the final analysis in whom TB was incidental to death, as
mentioned in the mortality review form which was com-
pleted by the mortality review panel). Indeed, the applica-
tion of modified criteria appears to be logical to permit a
more objective evaluation of Malaysian NTP. However,
because the WHO outcome criteria recommend reporting
the outcome for a complete cohort, the figure 67.26% is
appropriate for international comparison purposes.
In this study, defaulters were the second most common
group of patients in the unsuccessful treatment outcome
category. Our finding (8.93%) is somewhat comparable
to the results of studies from Singapore (9%), Germany
(10%), Cameron (20%) and Libya (28%) [4,17,22,27]. In
contrast, American and Norwegian studies showed rela-
tively lower defaulter rates among TB patients [15,28]. This
inconsistency in the findings might be the consequence of
Table 2 Clinical characteristics of the patients
Characteristics Patients n (%)
Form of TB
S+ PTB* 326 (97.02)
S+ PTB* and EPTB† 10 (2.98)





<4 weeks 76 (22.62)








No cavity 154 (45.83)
Single cavity 90 (26.79)
Two cavities 37 (11.01)




Acquired immunodeficiency syndrome 16 (4.76)
Other comorbidities 42 (12.50)
*Smear positive pulmonary tuberculosis; †Extrapulmonary tuberculosis.
Table 3 Treatment outcomes as per standard criteria
Treatment outcomes Patients n (%) Total n (%)
Successful
226 (67.26)Cured 41 (12.20)
Treatment completed 185 (55.06)
Unsuccessful
110 (32.74)
Treatment failure 0 (0)
Died 59 (17.56)
Defaulter 30 (8.93)
Transferred out 21 (6.25)
Table 4 Predictors of unsuccessful treatment outcome:
multiple logistic regression analysis
Independent variables B S.E p-value AOR (95% CI)
Male 0.767 0.299 .010 2.15 (1.20, 3.87)
Chinese -0.524 0.263 .057 0.59 (0.35, 1.07)
Foreigners 3.050 1.280 <.0005 21.24 (4.61, 97.94)
Illiterate 1.320 0.443 .003 3.72 (1.56, 8.87)
p-value of less than 0.05 in bold; Model summary (chi-square = 47.55, degrees
of freedom = 4, p = <.0005, pseudo R2 = .132).
Table 5 Predictors of mortality: multiple logistic
regression analysis
Independent variables B S.E p-value AOR (95% CI)
Male 0.580 0.523 .268 1.79 (0.64, 4.98)
Age* 0.027 0.013 .036 1.03 (1.01, 1.06)
History of ≥4 weeks cough 0.999 0.586 .088 2.72 (0.86, 8.57)
Lung cavities 1.980 0.493 <.0005 7.25 (2.76, 19.07)
High-grade sputum 2.420 0.765 .002 11.19 (2.50, 30.11)
Diabetes mellitus 0.701 0.372 .060 2.02 (0.97, 4.18)
Smoker 0.020 0.448 .965 1.07 (0.41, 2.36)
Alcoholism 0.934 0.394 .018 2.54 (1.17, 5.51)
p-value of less than 0.05 in bold; *Continuous variable; Model summary
(chi-square = 71.71, degrees of freedom = 8, p = <.0005, pseudo R2 = .216).
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differences in patient characteristics or as a result of varying
criteria of NTP to trace and follow-up the treatment
defaulters.
In the transferred out group, most of the patients were
foreigners and the ones who left the country. It is not
compulsory for the Malaysian immigration authorities to
expel the foreigners who are diagnosed with active TB.
However, usually the clinicians encourage sending such
patients to their home countries for further treatment.
In the present study, 12 out of 20 foreigners were trans-
ferred to their countries. However, the information
about their treatment outcome was not available. Simi-
larly, two foreigners defaulted from the treatment, pos-
sibly due to the fear of compulsory expulsion from the
country. Lack of follow-up of the transferred out pa-
tients was unfortunate, since these patients might con-
ceal their illness for the sake of living and securing their
jobs in Malaysia.
One of our study’s most important finding was the at-
tainment of low cure rate (12.20%) which was attributable
to the unavailability of sputum specimen for microscopy
during the last month of treatment. According to WHO, a
PTB patient can be declared as cured if he/she has docu-
mented evidence of treatment completion with negative
bacteriology result in the last month of treatment and on
at least one previous occasion [3]. In actual practice, meet-
ing this criterion is quite difficult. Usually after regular in-
take of anti-TB drugs for two to three months, patients
are unable to produce sputum throughout the remaining
period of their treatment. As a result, sputum specimen is
not available for bacteriology. Possible solutions to cope
with this challenge are sputum induction, gastric aspirates
or bronchoalveolar lavage [18] at set time points suggested
by WHO [3].
Studies from the United Kingdom also reported a low
cure rate owing to difficulties in obtaining sputum speci-
mens during the last month of the treatment [11,28].
Along the same lines, a recent global TB report showed
low cure rates among PTB patients in Australia and New
Zealand [1]. On the other hand, studies from Singapore,
Germany and Norway showed higher cure rates among
new smear positive PTB patients [4,15,27]. None of these
studies provided information about the sputum induction
during the last month of treatment. However, a Swiss
study reported when spontaneous sputum was not avail-
able from the patients, a chest therapist induced sputum
during the last month of TB treatment [16].
In multiple logistic regression analysis, male gender,
illiteracy and foreign nationality were the independent
predictors of unsuccessful treatment outcome. In com-
parison to Malaysians, foreigners had about 21 times
higher chance of unsuccessful treatment outcome. One of
the major reasons for this finding was the preferred expul-
sion of infected foreigners to their home countries. Like-
wise, illiteracy among the study patients was the second
highest predictor (OR 3.72) of unsuccessful treatment out-
come. A Malaysian study found a positive relationship be-
tween TB-related knowledge and education level of the
patients [29]. Low level of TB-related knowledge might be
a stronger barrier in completion of TB treatment. It could
be assumed that this subgroup of people might stop taking
anti-TB drugs upon resolving the TB-related signs and
symptoms. With regard to gender, males had 2.18 times
higher probability of unsuccessful treatment outcome
when compared with females. Earlier studies also reported
a direct association between male gender and the risk
of unsuccessful TB treatment outcome [4,28]. Higher
probability of unsuccessful outcome in men might be
attributed to their high risk behaviors such as alcohol,
substance and tobacco abuse [7].
We found that the risk factors for the patients’ mortality
due to TB were high-grade sputum and presence of lung
cavities at the start of treatment, alcoholism and older age.
Consistent with our findings, studies from Turkey and
China showed that extensive lung involvement was associ-
ated with higher mortality rate among PTB patients
[30,31]. In contrast, two American studies demonstrated
that the extent of lung involvement was negatively associ-
ated with patient death possibly due to the fact that the
presence of cavities might raise the probability of an early
diagnosis of TB in a patient [23,24]. When compared with
non-alcoholics, alcoholics had 2.54 times higher probabil-
ity of dying from TB. Our finding is similar to the findings
of a study which showed a positive association between al-
cohol use and mortality in TB patients [4]. Studies showed
that older patients are less likely to complete their treat-
ment due to death [25,28]. Common of these studies, this
study also showed that older patients had a greater prob-
ability of dying during their TB treatment.
With regard to the treatment duration, concurrent dia-
betes, presence of lung cavities at the start of TB treat-
ment and smoking were independent determinants of
longer treatment duration. Diabetes and smoking can
weaken the body’s immune system by affecting the cell-
mediated immunity [10,32,33]. Weakening of immune
system could delay the sputum conversion time and thus
Table 6 Predictors of prolonged treatment duration:
multiple logistic regression analysis
Independent variables B S.E p-value AOR (95% CI)
Unemployment -0.951 0.398 .017 0.39 (0.18, 0.84)
Lung cavities 0.981 0.375 .009 2.67 (1.29, 5.57)
High-grade sputum 0.662 0.371 .074 1.94 (0.94, 4.0)
Diabetes mellitus 1.920 0.421 <.0005 6.80 (2.98, 15.51)
Smoker 0.890 0.371 .016 2.43 (1.18, 5.03)
p-value of less than 0.05 in bold; Model summary (chi-square = 49.38, degrees
of freedom = 5, p = <.0005, pseudo R2 = .212).
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the treatment duration may be prolonged. With regard
to the cavitary disease, available literature confirmed that
patients exhibiting lung cavities at the time of their TB
diagnosis had longer treatment duration owing to ex-
tended sputum conversion time [16]. Likewise, this study
also showed that the probability of longer treatment dur-
ation was 2.67 times higher in patients with cavitary dis-
ease compared with those who had no evidence of lung
cavities at the time of TB diagnosis.
Interestingly, in our study, unemployed patients had
2.56 times higher chances of completing their TB treat-
ment in 6 months. One possible justification for this
finding might be that because of depression over being
jobless, unemployed patients visited the clinic more fre-
quently to seek health care, and thus enabled the clini-
cians to closely monitor the progress of treatment.
Conclusion
In this study, the TB treatment success rate was less
than the success target set by WHO. The cure rate was
only 12.20% because most of the patients did not report
sputum production during the last month of their TB
treatment. The lower treatment success rate was attrib-
uted to a higher proportion of the patients in died and
defaulter treatment outcome categories. In addition,
6.25% of patients in the transferred out category also led
to a lower treatment success rate.
The proportion of patients in successful outcome cat-
egory could be improved by closely monitoring the clin-
ical improvement in the patients with identified risk
factors. Similarly, more aggressive follow-up of treat-
ment defaulters and transferred out patients could also
improve the TB treatment success rate. The clinicians
may encourage the foreigners to complete their treat-
ment in Malaysia. Perhaps, this measure could improve
the treatment success rate.
To improve the cure rate, during the last month of TB
treatment, the clinicians should consider inducing spu-
tum in non-sputum producing patients. Finally, though
TB treatment outcome criteria set by WHO appears to
be clear and inclusive, there are limitations, and require
further improvements to permit an objective evaluation
of NTP.
Study limitations
The results of our study should be applied with caution
to evaluate the overall TB treatment success rate in
Malaysia. Because of industrial setup and tourism indus-
try, Penang has become multicultural state. As a result,
large number of foreigners and Malaysian citizens from
other parts of country are settled in Penang. Doubtless,
if diagnosed with active TB, these subsets of people are
more likely to have unsuccessful treatment outcome (i.e.,
defaulter and/or transferred out). Secondly, PGH is a
referral hospital for the Northern region of Malaysia.
Therefore, it is assumed that relatively complex TB pa-
tients consulted or were referred to PGH. Indeed, this
fact is further supported by a higher proportion of the
patients in the death category of treatment outcomes.
We conducted our study in Penang based on the rec-
ommendations of WHO to separately evaluate TB treat-
ment outcome at peripheral, district, and state levels [3].
Indeed, this strategy identifies the states or units which
are performing well and thus enables the NTP staff to
replicate successful practices elsewhere.
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